The Senate health committee sent stakeholders a draft of its cosmetics bill, obtained by Inside Health Policy , in a bid to gather input on the proposed federal oversight reforms, which include allowing HHS to suspend facilities or ingredient listing, requiring manufacturers to report adverse events to HHS within a set period of time, mandating manufacturing and processing facilities register with HHS, establishing labeling requirements, and allowing HHS to inspect facility records if it believes a cosmetic product is adulterated...